{
    "clinical_study": {
        "@rank": "99008", 
        "arm_group": [
            {
                "arm_group_label": "Albiglutide 30 mg weekly", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will be randomly assigned to double blind albiglutide 30 mg weekly treatment for 52 weeks"
            }, 
            {
                "arm_group_label": "Albiglutide 50 mg weekly", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will be randomly assigned to double blind albiglutide 50 mg weekly until Week 52"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will be randomly assigned to double blind matching albiglutide placebo administered weekly. Subjects will then cross-over to double-blind treatment with albiglutide 30 mg weekly at Week 24 until Week 52"
            }, 
            {
                "arm_group_label": "Liraglutide 0.9 mg daily", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will be randomly assigned to open-label liraglutide for 52 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to examine the efficacy and safety of 2 dose levels of weekly\n      subcutaneously injected albiglutide compared with placebo and an open label reference arm of\n      daily subcutaneous injections of liraglutide, in Japanese subjects with Type 2 diabetes\n      mellitus."
        }, 
        "brief_title": "A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with diagnosis of Type 2 Diabetes Mellitus, treated with diet and exercise\n             or a stable dose of 1 OAD at screening\n\n          -  Body mass index (BMI) 17 to 40 kg/ m2 inclusive\n\n          -  Subjects who are OAD na\u00efve, HbA1c between 7.0% and 10.0% at Screening and at Visit 2;\n             for subjects who enter the study with 1 OAD, HbA1c between 6.5% and 9.5% at Screening\n             and HbA1c between 7.0% and 10.0% at Visit 2\n\n          -  Creatinine clearance >30 mL/min (calculated using the Cockcroft-Gault formula)\n\n        Exclusion Criteria:\n\n          -  History of type 1 diabetes mellitus \u2022Female subject is pregnant, lactating, or <6\n             weeks postpartum\u2022\n\n          -  Clinically significant cardiovascular and/or cerebrovascular disease\n\n          -  Current ongoing symptomatic biliary disease, clinical signs or symptoms of\n             pancreatitis, or a history of chronic or acute pancreatitis, as determined by the\n             investigator\n\n          -  Serum amylase >=3 \u00d7ULN and/or serum lipase >=2 \u00d7 ULN and/or subject is experiencing\n             any symptoms possibly related to pancreatitis\n\n          -  Prior use of a TZD or GLP-1R agonist within 4 months before Screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "475", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01733758", 
            "org_study_id": "113121"
        }, 
        "intervention": [
            {
                "arm_group_label": "Albiglutide 30 mg weekly", 
                "description": "Albiglutide will be available as  a pen injector that delivers 30mg of albiglutide", 
                "intervention_name": "Albiglutide 30 mg weekly", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Albiglutide 50 mg weekly", 
                "description": "Albiglutide will be available as a pen injector that delivers 50mg of albiglutide", 
                "intervention_name": "Albiglutide 50 mg weekly", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Albiglutide 30 mg weekly"
                ], 
                "description": "Albiglutide matching placebo will be available as a pen injector", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Liraglutide 0.9 mg daily", 
                "description": "Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose", 
                "intervention_name": "Liraglutide 0.9 mg daily", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "albiglutide", 
            "Japanese", 
            "GSK716155", 
            "Type 2 diabetes mellitus", 
            "glucagon-like peptide 1"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gunma", 
                        "country": "Japan", 
                        "zip": "370-3573"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tochigi", 
                        "country": "Japan", 
                        "zip": "329-0433"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "103-0027"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The HbA1c will be assessed to compare two different doses of albiglutide with placebo. Change from baseline will be calculated as: HbA1c value at Week 24 minus HbA1c value at Baseline", 
            "measure": "Change from Baseline at Week 24 of glycosylated hemoglobin (HbA1c).", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733758"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "HbA1c will be assessed through Week 52 to compare albiglutide and placebo.", 
                "measure": "Change from baseline in HbA1c over time", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of treatment (Week 52)"
            }, 
            {
                "description": "The proportion of subjects at HbA1c <6.5% and ,7.0% through Week 52 to compare albiglutide and placebo.", 
                "measure": "The proportion of subjects at HbA1c goals of <6.5% and <7.0% over time", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of treatment (Week 52)"
            }, 
            {
                "description": "FPG will be assessed through Week 52 comparing albiglutide versus placebo", 
                "measure": "Change from Baseline in Fasting Plasma Glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of treatment (Week 52)"
            }, 
            {
                "description": "Body weight will be assessed through Week 52 to compare albiglutide and placebo.", 
                "measure": "Change from baseline in body weight over time", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of treatment (Week 52)"
            }, 
            {
                "description": "Time to study treatment withdrawal will be assessed through Week 52 for any reason and for hyperglycemia to compare albiglutide and placebo.", 
                "measure": "Time to withdrawal from randomly assigned treatment for any reason, and time to withdrawal from randomly assigned treatment due to hyperglycemia over time", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of treatment (Week 52)"
            }, 
            {
                "description": "Comparison of number of participants with adverse events after treatment with albiglutide and placebo", 
                "measure": "Number of participants with adverse events", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 52 weeks"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}